Clinical Programs

Target:
Pancreatic Cancer

Active, Not Recruiting

Trial of NanoPac in Patients With Locally Advanced Pancreatic Adenocarcinoma

Target:
Lung Cancer

Active, Not Recruiting

Trial of NanoPac Intratumoral Injection in Lung Cancer

This trial evaluates the safety, tolerability, and preliminary efficacy of up to three injections of NanoPac (LSAM paclitaxel) for Suspension administered into the lung tumors and lymph nodes of patients with lung cancer. Patients with non-small cell lung cancer or small cell lung cancer are eligible for this study.

Four sites in the U.S. will be participating. If you are over 18 and have been diagnosed with lung cancer you may qualify for this study.

Target:
Bladder Cancer

Completed

Evaluation of NanoDoce in Participants with Urothelial Carcinoma

This clinical trial is studying the administration of NanoDoce (LSAM docetaxel) for Suspension as a direct injection to the bladder wall immediately after tumor resection and as an intravesical instillation in an Induction and Maintenance schedule. Patients will be stratified into two treatment groups, Group 1 – non-muscle invasive bladder cancer (NMIBC) and Group 2 – muscle invasive bladder cancer (MIBC). All participants will receive NanoDoce, and will be evaluated for safety and tolerability, as well as the potential effects of NanoDoce on urothelial carcinoma. A total of 36 patients were enrolled into the study.

Target:
Pancreatic Mucinous-Cystic Neoplasm

Completed

Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac in Subjects With Mucinous Cystic Pancreatic Neoplasms

Target:
Cutaneous Metastases

Completed

Study of Topical SOR007 for Cutaneous Metastases

This trial evaluated the safety, tolerability and preliminary efficacy of three concentrations (0.15%, 1.0%, and 2.0%) of SOR007 (topical submicron particle paclitaxel in anhydrous base) applied to patients with non-melanoma cutaneous metastases primarily of breast cancer. The trial included a dose escalation phase and continued into a dose expansion phase at the 2% strength. A total of 23 patients were enrolled into the study.

Target:
Peritoneal Cancers

Completed

Trial of NanoPac in Patients with Peritoneal Cancers

This trial evaluated the safety, tolerability, and preliminary efficacy of NanoPac (LSAM paclitaxel) for Suspension administered via intraperitoneal (IP) infusion once every 28 days until disease progression or unacceptable toxicity. Patients with refractory malignancies principally confined to the peritoneal cavity were eligible for this study. A total of 22 patients were enrolled into the study.

Target:
Ovarian Cancer

Completed

Phase II Study of Intraperitoneal NanoPac in Patients With Ovarian Cancer

This trial evaluated the safety, tolerability, and preliminary efficacy of NanoPac (LSAM paclitaxel) for Suspension administered via intraperitoneally (IP) instillation at the end of post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy. Women with primary and recurrent ovarian cancer scheduled for cytoreductive surgery were eligible for this study. A total of 10 patients were enrolled into the study.

Target:
Prostate Cancer

Completed

Trial of NanoPac Focal Therapy in Subjects with Prostate Cancer

This trial evaluated the safety, tolerability, and preliminary efficacy of a single injection of NanoPac (LSAM paclitaxel) for Suspension administered into the prostate lobe of men with prostate cancer four weeks prior to scheduled prostatectomy. A total of 16 patients were enrolled into the study.